1
To commercially available 10-bromodecanoic acid (1 g, 3.98 mmol), NH 4 OH (40 mL, 25% in H 2 O) was added and stirred overnight. Upon completion, the mixture was evaporated to dryness. Water (2.1 mL), tert-butanol (2.1 mL, 22.3 mmol), NaOH (0.17 g, 4. 18 mmol) and di-tert-butyl dicarbonate (0.91 g, 4.18 mmol) were added to the crude amine and stirred for 2 days at room temperature. The reaction was quenched by adding water (4.8 mL) and 1 M HCl (2 mL), extracted into ethyl acetate (3×10 mL), washed with brine, dried over Na 2 SO 4 and concentrated to provide 30 as a white solid (1.02 g, 3.55 mmol, Yield = 89%). 
2-Cyclohexylethanaminium acetate, 31. 2
To commercially available 2-(1-cyclohexenyl)ethanamine (1.11 mL, 7.97 mmol) in methanol (83 mL), 10% palladium on carbon (0.50 g, 4.70 mmol) and acetic acid (0.83 mL, 14.5 mmol) were added. The suspension was stirred at room temperature and atmospheric pressure under an atmosphere of hydrogen for 3 days. The reaction mixture was filtered through Celite ® , washed with methanol and the filtrate was concentrated to provide 31 as a golden yellow viscous oil in quantitative yield (1.81 g). (10-Aminodecanoyl)-Ser-Lys-2-cyclohexylethylamide, 10. Fmoc-Ser(t-Bu)-Lys(Boc)-hydrazinobenzoyl resin (29, 100 mg) was swelled in DMF for at least 1 h and treated with 20% piperidine/DMF (3×3 mL) for 10 min per treatment. After the third treatment, the resin
S 3
was washed with DMF (3×3 mL), DCM (3×3mL) and DMF (3×3 mL). A coupling solution of DIPEA (85.3 μL, 0.49 mmol), HATU (93.2 mg, 0.245 mmol) and 30 (70.4 mg, 0.245 mmol) dissolved in DMF (2 mL) was added to the deprotected resin. Coupling was repeated twice for 1 h each time. The coupling mixture was drained and the resin was washed with DMF (5×2 mL), DCM (3×2 mL), MeOH (3×2 mL) and Et 2 O (3×2 mL) and left to dry in a desiccator overnight. Oxidative cleavage occurred by suspending the resin in DCM (2 mL), Cu(OAc) 2 .H 2 O (4.4 mg, 0.022 mmol), pyridine (53.9 μL, 0.67 mmol) and 31 (43.1 mg, 0.34 mmol). The reaction mixture was shaken in an open syringe at room temperature for 4 h. The resin was drained and washed with DCM (4×3 mL); the filtrate was washed with 1 M HCl and brine and concentrated under a flow of nitrogen. Deprotection using TFA/TIPS/H 2 O for 1 h (2 mL, 95:2.5:2.5, v/v) led to the formation of 10 which was purified by preparative LCMS to provide a yellow oil (9 mg, Yield = 30%). 1 H NMR (500 MHz, MeOD) δ ppm 8.22 (1H, s), m), 3.82 (1H, dd, J = 10.5, 5.6 Hz), m) Synthesis of peptidomimetics 1-28, excluding 10.
11-(tert-butoxycarbonylamino)undecanoic acid (32).

1
Commercially available 11-aminoundecanoic acid (1.00 g, 4.98 mmol) was added to a round bottom flask containing water (2.4 mL), tert-butanol (2.4 mL), NaOH (0.21 g, 5.23 mmol, 1.05 eq) and Boc-anhydride (1.14 g, 5.22 mmol, 1.05 eq). The reaction mixture was stirred for 2 days at room temperature. The reaction was quenched by adding water (5.4 mL) and acidified using 1 M HCl (2.3 mL). The reaction mixture was extracted into ethyl acetate; the organic layer washed with brine, dried over Na 2 SO 4 and concentrated to generate the desired product as a yellow oil (0.84 g, 2.77 mmol, Yield = 56% 
9-(tert-butoxycarbonylamino)nonanoic acid (33).
1 Using a literature procedure, 3 9-bromononanoic acid (0.46 g, Yield = 21.4%) was synthesised using Jones reagent (2M, 18 mL) in acetone (18 mL) from commercially sourced 9-bromononan-1-ol (2 g, 0.45 mol). Tert-butoxycarbonyl protection was carried out as described above to afford 33 which was isolated as an off-white solid (0.49g, Yield = 64%). 1 H NMR (400 MHz, CDCl 3 ) δ 4.52 (1H, s), 3.10 (2H, q, J = 6.8 Hz), 2.33 (2H, t, J = 7.5 Hz), 1.66 -1.56 (2H, m), 1.51 -1.41 (11H, m), 1.37 -1.27 (8H, m). 13 C NMR (100 MHz, CDCl 3 ) δ 40. 72, 34.11, 30.11, 29.16, 28.56, 28.36, 26.82, 24.83, 14.34 
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8-(tert-butoxycarbonylamino)octanoic acid (34).
1, 4
The product was synthesized according to a previously reported literature procedure and was isolated as a colourless oil (1.17 g, Yield = 59.7%). 
8-(1H-imidazol-1-yl)octanoic acid (35).
5
Following a previously reported literature procedure, tert-butyl 8-bromooctanoate, was synthesized from 8-bromooctanoic acid using t-BuOH (3 eq), DCC (1.15 eq), DMAP (0.1 eq) in DCM (6 mL) and stirred for 2 days at room temperature. The resulting ester was treated with sodium imidazolide (2 eq) in the presence of 18-crown-6 (2.1 eq) and DMF (12 mL) for 4.5 h at room temperature under nitrogen as described by Devadas et al. 7 Water (12 mL) was added and extracted into ethyl acetate (3×15 mL). The organic layer was washed with brine (2×15 mL), dried over MgSO 4 and concentrated under reduced pressure to give tert-butyl -8-(1H-imidazol-1-yl) This synthesis was applied in the synthesis of compounds 36-38 below.
9-(1H-imidazol-1-yl)nonanoic acid (36).
4
The product was obtained as a pale yellow oil (1.12 g, Yield = quant.) 1 H NMR (400 MHz, MeOD) δ 8.98 (1H, s), m), m), 4.26 (2H, t, J = 7.3 Hz), 2.29 (2H, t, J = 7.4 Hz) 
10-(1H-imidazol-1-yl)decanoic acid (37)
The product was obtained as a white solid (0.25 g, Yield = quant. 
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11-(1H-imidazol-1-yl)undecanoic acid (38). 7 The product was obtained as a white solid (0.32 g, Yield = quant. Compounds 39-42 were synthesised, in quantitative yields, in the same manner as 35-38 using 2-methylimidazole (2 eq), DMF, NaH (3 eq.) and 18-crown-6 (3.1 eq.). The compounds were used without further purification.
8-(2-methyl-1H-imidazol-1-yl)octanoic acid (39).
The product was obtained as a pale yellow oil (1.48 g, quant. 
10-(Tert-butoxycarbonyl)methylaminodecanoic acid (43)
To 10-bromodecanoic acid (0.5 g, 1.99 mmol), methylamine (10 mL, 252.7 mmol) was added and left stirring at room temperature overnight. The reaction mixture was concentrated under reduced pressure to give an off-white solid. The crude product was tert-butoxycarbonyl protected as described above to afford a pale yellow oil. The crude product was purified by preparative LCMS to give a colourless oil (0.27 g, Yield = 45% 
11-N-Boc-aminoundecanoic acid-Ser(t-Bu)-Lys(Boc)-H (44).
The Fmoc protecting group was removed from Fmoc-Ser(t-Bu)-Lys(Boc)-2-ClTrt (Loading 0.61 mmol/g, 103 mg) following treatment with 20% piperidine/DMF (3 mL). A coupling solution of DIPEA (109 μL, 0.63 mmol), HBTU (119 mg, 0.31 mmol) and 32 (94.7 mg, 0.31 mmol) dissolved in DMF (2 mL) was added to the deprotected resin. Coupling was repeated twice for 1 h each time. The coupling mixture was drained and the resin was washed with DMF (5×2 mL), DCM (3×2 mL), MeOH (3×2 mL) and Et 2 O (3×2 mL) and dried in a desiccator overnight. The peptide was cleaved off the chlorotrityl resin following treatment with 0.5% TFA/DCM (2×3 mL) for 30 min each time to provide 11-N-Boc-aminoundecanoic acid-Ser(t-Bu)-Lys(Boc)-OH which was purified using preparative LCMS to provide a yellow oil (19 mg, yield = 45%) and used in the subsequent reaction. HRMS (ESI) m/z calcd for C 34 (11-Aminoundecanoyl)-Ser-Lys-2-cyclohexylethylamide (9). 7 To 44 (19 mg) in DMF (1 mL), DIPEA (20.7 μL), EDCI·HCl (7.04 mg, 0.037 mmol, 1.3 eq), HOAt (5.0 mg, 0.037 mmol, 1.3 eq) and 31 (10.6 mg, 0.057 mmol, 2 eq) were added. The suspension was stirred for 4 days at room temperature. Water (2 mL) was added, the reaction mixture was extracted into ethyl acetate (3×10 mL) and washed with brine. The organic layer was concentrated and protecting groups were removed following treatment with TFA/TIPS/H 2 O (1 mL, 95:2.5:2.5) for 1 h. Purification was achieved using preparative LCMS. The resulting product was 9 as a glassy translucent formic acid salt (11 mg, Yield = 28% 
(9-Aminononanoyl)-Ser-Lys-2-cyclohexylethylamide (11).
This product was synthesised from 33 using the same method as compound 10 described above. The final product was a yellow oil (23 mg, Yield = 64%). 
(8-Aminooctanoyl)-Ser-Lys-2-cyclohexylethylamide (12)
This product was synthesised from 34 using the same method as compound 10 described above. The final product was a yellow oil (6 mg, Yield = 17%). 
11-(1H-imidazol-1-yl)undecanoyl-Ser-Lys-2-cyclohexylethylamide (1) 7
This product was synthesised from 38 using the same method as compound 9 but using HATU (93.2 mg, 3 eq), DIPEA (85.6 μL, 6 eq) and 31 over 2 days. The final product was a 
10-(1H-imidazol-1-yl)decanoyl-Ser-Lys-2-cyclohexylethylamide (2)
This product was synthesised from 37 using the same method as compound 10 described above. The final product was a yellow oil (2.9 mg, Yield = 10%). 
9-(1H-imidazol-1-yl)nonanoyl-Ser-Lys-2-cyclohexylethylamide (3)
This product was synthesised from 36 using the same method as compound 10 described above. The final product was a yellow oil (8 mg, Yield = 22%). 1 H NMR (500 MHz, MeOD) δ 8.98 (1H, s), 7.69 (1H, t, J = 1.8 Hz), 7.59 (1H, t, J = 1.8 Hz), m), m), 3.86 (1H, dd, J = 10.5, 5.6 Hz), m), m) 
8-(1H-imidazol-1-yl)octanoyl-Ser-Lys-2-cyclohexylethylamide (4)
This product was synthesised from 35 using the same method as compound 10 described above. The final product was generated as a yellow oil (22 mg, Yield = 62%). 
11-(2-Methyl-1H-imidazol-1-yl)undecanoyl-Ser-Lys-2-cyclohexylethylamide (5)
This product was synthesised from 42 using the same method as compound 10 described above. The final product was generated as a yellow oil (11 mg, Yield = 35% 
10-(2-Methyl-1H-imidazol-1-yl)decanoyl-Ser-Lys-2-cyclohexylethylamide (6)
This product was synthesised from 41 using the same method as compound 10 described above. The final product was generated as a yellow oil (5 mg, Yield = 12% S 1 0 9-(2-Methyl-1H-imidazol-1-yl)nonanoyl-Ser-Lys-2-cyclohexylethylamide (7) This product was synthesised from 40 using the same method as compound 10 described above. The final product was generated as a yellow oil (11 mg, Yield = 30% 
8-(2-Methyl-1H-imidazol-1-yl)octanoyl-Ser-Lys-2-cyclohexylethylamide (8)
This product was synthesised from 39 using the same procedure as compound 10 described above. The final product was generated as a yellow oil (1.72 mg, Yield = 5%). 
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Acetyl-Ser-Lys-2-cyclohexenylethylamide (14) Following the removal of the Fmoc group using 20% piperidine/DMF, Ser(t-Bu)-Lys(Boc)-hydrazinobenzoyl resin was treated with a mixture of acetic anhydride (10% v/v), DIPEA (20% v/v) in DMF (3 mL) for 1 h at room temperature. The resin was washed, dried and cleaved oxidatively using the same method as compound 10 to afford compound 14. Following purification, 14 was generated as a yellow oil (8 mg, Yield = 38%,). (10-Aminononanoyl)-Ser-Lys-2-cyclohexenylethylamide (16) This product was synthesised from commercially available 2-(1-cyclohexenyl)-ethanamine using the same method as compound 10 described above. The final product was generated as a yellow oil (11 mg, Yield = 37%). (1H-imidazol-1-yl) undecanoyl-Ser-Lys-2-cyclohexenylethylamide (17) This product was synthesised from commercially available 2-(1-cyclohexenyl)-ethanamine using the same method as compound 10 described above. The final product was a brown oil (10.2 
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10-(1H-imidazol-1-yl)decanoyl-Ser-Lys-2-cyclohexenylethylamide (18)
This product was synthesised from commercially available 2-(1-cyclohexenyl)-ethanamine using the same method as compound 10 described above. The final product (18) was a yellow oil (9 mg, Yield = 30%). 
11-(2-Methyl-1H-imidazol-1-yl)undecanoyl-Ser-Lys-2-cyclohexenylethylamide (19)
This product was synthesised from commercially available 2-(1-cyclohexenyl)-ethanamine using the same method as compound 10 described above. The final product was a yellow oil (14 mg, Yield = 43%). 
10-(2-Methyl-1H-imidazol-1-yl)decanoyl-Ser-Lys-2-cyclohexenylethylamide (20)
This product was synthesised from commercially available 2-(1-cyclohexenyl)-ethanamine using the same method as compound 10 described above. The final product was a yellow oil (13 mg 
(10-Aminodecanoyl)-Ser-Lys-OH (26)
Using Wang resin (Loading: 0.67 mmol/g, 100 mg), 30 and previously described Fmoc chemistry, this product was generated as a yellow oil (9.9 mg, Yield = 30%). 
7-(9H-fluoren-9-ylmethoxycarbonylamino)heptanoic acid (45)
Commercially available 7-aminoheptanoic acid (0.5 g, 3.46 mmol) was dissolved in 10% Na 2 CO 3 (36 mL) and 1,4-dioxane (24 mL); Fmoc-Cl (1.5 eq) was sunsequently added in portions. The reaction mixture was left stirring overnight at room temperature and extracted with diethylether (2×40 mL). The aqueous layer was acidified with 2 M HCl to pH1. The white solid was filtered, washed with water and dried in a desiccator to give the desired product as a white solid (1.18 g, Yield = 93%). 
Gly-(7-aminoheptanoyl)-Ser-Lys-2-cyclohexylethylamide (27).
Using standard Fmoc chemistry, 45 (168 mg, 0.46 mmol) and Fmoc-Gly-OH (137 mg, 5 eq) were coupled to Fmoc-Ser(t-Bu)-Lys(Boc)-hydrazinobenzoyl resin (150 mg) as previously described. Cleavage was carried out using excess 31 (78 mg, 0.42 mmol). The final product was achieved as a yellow oil (1.8 mg, Yield = 3% 
Ala-(7-aminoheptanoyl)-Ser-Lys-2-cyclohexylethylamide (28)
This product was synthesised in the same manner as 27 using Fmoc-Ala-OH (143 mg). The final product was achieved as yellow oil (2.6 mg, Yield = 5% Alignment also shows residues within 6 Å of the peptide pocket in blue, and their equivalents in other NMT enzymes.
times to completely wash away the original drop solution and left to soak for at least 20 hours. Protein expression of PvNMT and crystallisation of the ternary complex with the nonhydrolysable co-factor and compound 10 bound was essentially as described previously. 10 
Data collection and refinement.
X-ray diffraction data were collected on synchrotron beamlines at the Diamond Light Source and processed using XDS 11 and SCALA 12 implemented within xia2. 13 Data collection and refinement statistics are summarised in Table S1 . For R free calculations, 5% of the data were excluded. Cycles of refinement using maximum likelihood methods implemented in REFMAC 14 were interspersed with model building and adjustment using COOT. 15 LmNMT crystals have a single protein molecule in the assymetric unit, with only N-terminal residues preceding Ala11 (numbering as in full-length native LmNMT protein) not visible in the electron density. For PvNMT, complete chains (corresponding to residues 27 -410, numbering as in full-length protein) can be traced for two of the three molecules in the asymmetric unit. N-terminal residues in all three chains and loop residues 227 -238 in chain C have not been modeled and these are assumed to be disordered. The final protein structure models display good geometry with only 0.3% (corresponding to the equivalent amino acid residues PvNMT Phe336 and LmNMT His347) lying outside the preferred regions of the Ramachandran plot. Table S1 . X-ray data collection and refinement statistics.
PDB accession code
PvNMT-NHM-10 4c68
LmNMT-MyrCoA-10 4c7h
LmNMT-MyrCoA-46 4c7i Figure S1: Electron density maps relating to co-factor analogue (NHM) and ligand 10 bound to PvNMT. The ligands are shown in stick representation, coloured by atom; carbon (green), oxygen (red), sulphur (yellow), phosphorus (fuchsia) and nitrogen (blue) with associated refined electron density map (2mF O -dF C ) contoured at a level of 1 σ. The top panel pair shows ligands bound to protein chain B, with the right-hand side zooming in on a region between the S atom of the co-factor and the N atom at the end of the long ligand alkyl chain. This N-terminus of ligand 10 has been modelled in two slightly different alternate conformations when bound to protein chain A (bottom panel pair). The N-terminal amine (Gly-NH 2 ) of a substrate peptide would need to flip its carbonyl group to satisfy both equivalent positions. In the cis position to the carbonyl, the N-terminal amino group would be able to make a close contact to the carboxylate of Leu410. In the trans position the carbonyl could interact with the conserved active site residue Thr197 and the chain would adopt an orientation more similar to that seen in the ternary structure of LmNMT-MyrCoA-10. The requirement for conformational flexibility at the N-terminus of a substrate could explain the strict conservation of Gly at this position of the myristoylation sequence motif. There is no evidence from the electron density maps to suggest the presence of ligand 10 in the equivalent binding region of PvNMT protein chain C, which appears to be much more accessible to solvent due to crystal packing. Figure S2 : Electron density maps relating to MyrCoA and compound 10 bound to LmNMT. Initial electron density maps calculated at preliminary stages of refinement (left-hand panels) reveal regions of positive (red) and negative (green) density in the difference map (mF O -dF C ) when MyrCoA and ligand 10 (purple and red ball-and-stick, respectively) were placed in the starting model. Most of the negative density regions were accounted for by the subsequent addition of water or DMSO co-solvent molecules (grey atoms). The electron density remaining was satisfied by modelling the presence of a small proportion (20%) of myristoyl-10 (yellow) and CoA (green) as putative products of an enzyme-catalysed reaction. The right-hand panels show the final refined electron density map (2mF O -dF C ) around the ligands contoured at a level of 0.5 σ and with associated individual ligand pairs (MyrCoA and compound 10 reactants or CoA and myristoyl-10 products) in cylinder representation. The bottom panel shows the mixture of ligands present in the final refined model (80% reactant and 20% product) shown as ball-andstick to aid identification. Electron density figures were made using the program CCP4mg. 
Kinetic studies of Compound 10.
As depicted in Figure S3 , following kinetic studies, compound 10 showed characteristics similar to that of a competitive inhibitor for PvNMT.
